Cantor Fitzgerald Maintains Tourmaline Bio(TRML.US) With Buy Rating
Chardan Capital Initiates Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $70
Tourmaline Bio Initiated at Buy by Chardan Capital
Tourmaline Bio Price Target Announced at $70.00/Share by Chardan Capital
Tourmaline Bio Analyst Ratings
Jefferies Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $64
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $63
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $63
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and Tourmaline Bio (TRML)
Truist Cuts Price Target on Tourmaline Bio to $63 From $74, Keeps Buy Rating
BMO Capital Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $50
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Wedbush Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $43
Tourmaline Bio Price Target Raised to $43.00/Share From $42.00 by Wedbush
Tourmaline Bio Is Maintained at Outperform by Wedbush
Truist Financial Sticks to Their Buy Rating for Tourmaline Bio (TRML)
Buy Rating for Tourmaline Bio: Potential of Pacibekitug and Upcoming CKD Data Release
Wedbush Lifts Price Target on Tourmaline Bio to $43 From $42, Keeps Outperform Rating
Tourmaline Bio Analyst Ratings
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65